Ocera Therapeutics, Inc.
OCRX
OCRX was delisted on the 8th of December, 2017.
31 hedge funds and large institutions have $34.4M invested in Ocera Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
3% more capital invested
Capital invested by funds: $33.3M → $34.4M (+$1.04M)
6% less funds holding
Funds holding: 33 → 31 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.02M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.97M |
| 3 |
DM
Deerfield Management
New York
|
+$1.15M |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$1.15M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$1.82M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.16M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$423K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$187K |
| 5 |
Renaissance Technologies
New York
|
-$148K |
OCRX Hedge Fund Activity: Q3 2014 in Review
31 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q3 2014, worth a combined $34.4M — up 3.1% from $33.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of OCRX and 5 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 12 added.
The largest buyer was Great Point Partners, adding an estimated $9.02M. The largest seller was Jennison Associates, exiting entirely with an estimated $1.82M sold.
- 31 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q3 2014, down from 33 in Q2 2014.
- Funds reported $34.4M of Ocera Therapeutics, Inc. stock for Q3 2014, up 3.1% quarter-over-quarter.
- 5 funds opened new Ocera Therapeutics, Inc. positions in Q3 2014 and 7 closed out, a net change of -2 holders.
- The largest Ocera Therapeutics, Inc. buyer in Q3 2014 was Great Point Partners, an estimated $9.02M added.
- The largest Ocera Therapeutics, Inc. seller in Q3 2014 was Jennison Associates, an estimated $1.82M sold.
Based on aggregated 13F filings for Q3 2014.